

PCT COOPERATION TREATY

04.1.30

SOEI

PCT

NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

HASEGAWA, Yoshiki
SOEI PATENT AND LAW FIRM, Ginza
First Bldg.
10-6, Ginza 1-chome
Chuo-ku, Tokyo 104-0061
Japan

Date of mailing (day/month/year) 20 January 2004 (20.01.2004)	
Applicant's or agent's file reference FP03-0298-00	IMPORTANT NOTIFICATION
International application No. PCT/JP2003/013932	International filing date (day/month/year) 30 October 2003 (30.10.2003)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 30 October 2002 (30.10.2002)
Applicant HISAMITSU PHARMACEUTICAL CO., INC. et al	

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable) The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- (If applicable) An asterisk(*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
30 Octo 2002 (30.10.2002)	2002-316586	JP	19 Dece 2003 (19.12.2003)

内 容	確 認	データ入力
OA・許可 提出報告 問い合わせ	鈴木	

 The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Richard SARMIR (Fax 338 9090)
Facsimile No. (41-22) 338.90.90	Telephone No. (41-22) 338 8434

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTICE INFORMING THE APPLICANT OF THE
COMMUNICATION OF THE INTERNATIONAL
APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

To:

HASEGAWA, Yoshiki
SOEI PATENT AND LAW FIRM, Ginza First Bldg.
10-6, Ginza 1-chome
Chuo-ku, Tokyo 104-0061
JAPONDate of mailing (day/month/year)
13 May 2004 (13.05.2004)Applicant's or agent's file reference
FP03-0298-00

IMPORTANT NOTICE

International application No.
PCT/JP2003/013932International filing date (day/month/year)
30 October 2003 (30.10.2003)Priority date (day/month/year)
30 October 2002 (30.10.2002)

Applicant

HISAMITSU PHARMACEUTICAL CO., INC. et al

1. Notice is hereby given that the International Bureau has **communicated**, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this notice:

EP, US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

None

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this notice is a copy of the international application as published by the International Bureau on 13 May 2004 (13.05.2004) under No. WO 2004/039975

4. **TIME LIMITS for filing a demand for international preliminary examination and for entry into the national phase**

The applicable time limit for entering the national phase will, **subject to what is said in the following paragraph**, be **30 MONTHS** from the priority date, not only in respect of any elected Office if a demand for international preliminary examination is filed before the expiration of **19 months** from the priority date, but also in respect of any designated Office, in the absence of filing of such demand, where Article 22(1) as modified with effect from 1 April 2002 applies in respect of that designated Office. For further details, see *PCT Gazette* No. 44/2001 of 1 November 2001, pages 19926, 19932 and 19934, as well as the *PCT Newsletter*, October and November 2001 and February 2002 issues.

In practice, time limits other than the 30-month time limit will continue to apply, for various periods of time, in respect of certain designated or elected Offices. For regular updates on the applicable time limits (20, 21, 30 or 31 months, or other time limit), Office by Office, refer to the *PCT Gazette*, the *PCT Newsletter* and the *PCT Applicant's Guide*, Volume II, National Chapters, all available from WIPO's Internet site, at <http://www.wipo.int/pct/en/index.html>.

For filing a demand for international preliminary examination, see the *PCT Applicant's Guide*, Volume I/A, Chapter IX. Only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination (at present, all PCT Contracting States are bound by Chapter II).

It is the applicant's sole responsibility to monitor all these time limits.

内 容	確 認	データ入力
OA・許可 提出報告 問い合わせ	富 16.5.26 永	

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Yoshiko Kuwahara

Facsimile No.+41 22 740 14 35

Facsimile No.+41 22 338 90 90

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2004 年 5 月 13 日 (13.05.2004)

PCT

(10) 国際公開番号
WO 2004/039975 A1

(51) 国際特許分類⁷: C12N 15/09, C12Q 1/68, G01N 33/50

(21) 国際出願番号: PCT/JP2003/013932

(22) 国際出願日: 2003 年 10 月 30 日 (30.10.2003)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:
特願 2002-316586
2002 年 10 月 30 日 (30.10.2002) JP

(71) 出願人 (米国を除く全ての指定国について): 久光製薬株式会社 (HISAMITSU PHARMACEUTICAL CO., INC.) [JP/JP]; 〒841-0017 佐賀県 鳥栖市 田代大官町 408 Saga (JP). 千葉県 (CHIBA-PREFECTURE) [JP/JP]; 〒260-8667 千葉県 千葉市中央区 市場町1番1号 Chiba (JP).

(72) 発明者; および

(75) 発明者/出願人 (米国についてのみ): 中川原 章 (NAKAGAWARA, Akira) [JP/JP]; 〒260-0801 千葉県 千葉市

中央区 仁戸名町 666-2 千葉県がんセンター内 Chiba (JP). 大平 美紀 (OHIRA, Miki) [JP/JP]; 〒260-0801 千葉県 千葉市中央区 仁戸名町 666-2 千葉県がんセンター内 Chiba (JP).

(74) 代理人: 長谷川 芳樹, 外 (HASEGAWA, Yoshiki et al.); 〒104-0061 東京都 中央区 銀座一丁目 10 番 6 号 銀座ファーストビル 創英国際特許法律事務所 Tokyo (JP).

(81) 指定国 (国内): US.

(84) 指定国 (広域): ヨーロッパ特許 (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

添付公開書類:
— 国際調査報告書

2 文字コード及び他の略語については、定期発行される各 PCT ガゼットの巻頭に掲載されている「コードと略語のガイダンスノート」を参照。

(54) Title: NUCLEIC ACIDS ISOLATED FROM NEUROBLASTOMA AT STAGE 4S

(54) 発明の名称: 4 s 期神経芽細胞腫から単離された核酸

(57) Abstract: Prognosis (in particular, determination of the progress stage and judgment of neuroblastoma at stage 4s) of neuroblastoma is diagnosed by using a diagnostic agent for the prognosis of neuroblastoma and a diagnostic kit comprising a nucleic acid probe, a primer or a nucleic acid microarray with the use of a nucleic acid comprising a sequence selected from among the nucleic acid sequences represented by SEQ ID NOS:1 to 174, fragments thereof and combinations of the same.

(57) 要約: 配列表の配列番号 1 ないし 174 に記載の核酸配列からなる群より選ばれる 1 つの配列からなる核酸若しくはその断片等、或いはその組み合わせを利用した核酸プローブ、プライマーまたは核酸マイクロアレイからなる、神経神経芽細胞腫の予後診断剤および診断キットを用いて、神経芽細胞腫の予後 (特に、進行度分類および 4 s 期神経芽細胞腫の判定) を診断する。

WO 2004/039975 A1